Michael LaPelusa: Tissue and imaging biomarkers of response to neoadjuvant IO in patients with resectable HCC
Michael LaPelusa, Hematology/Oncology fellow at MD Anderson Cancer Center, shared on X about recent paper by him as first author, titled “Tissue and Imaging Biomarkers of Response to Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Patients with Resectable Hepatocellular Carcinoma” published on Oncology Karger.
Authors: Michael LaPelusa, Shadi Chamseddine, Hop Sanderson Tran Cao, Lianchun Xiao, Elshad Hasanov, Priya Bhosale, Hesham M. Amin, Yehia I. Mohamed, Betul Gok Yavuz, Yara Sakr, Li Xu, Ian Hu, Sunyoung S. Lee, Divya Sakamuri, Sonali Jindal, Van Nguyen, Michael A. Curran, Ryan Sun, Asif Rashid, Dan Gabriel Duda, Padmanee Sharma, Aliya Qayyum, Ahmed Omar Kaseb.
“Out now in Oncology Karger – our paper on tissue and imaging biomarkers of response to neoadjuvant immunotherapy in patients with resectable HCC!
Excited to see if, in the near future, we can predict who will have a major pathological response.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023